Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-BVD-523 in Healthy Male Subjects
NCT02994732Phase 1Completed
- Sponsor
- BioMed Valley Discoveries
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ulixertinib in solid tumor, sponsored by BioMed Valley Discoveries. Primary endpoints: Time to Maximum Concentration at 5 days, Maximum Concentration at 5 days and 6 more. Started Jan 2017; status: completed.
02
Drugs
ulixertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02994732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994732.